Statins and the risk of Parkinson disease: An update on the controversy

Expert Opinion on Drug Safety

Volumn 8, Issue 3, 2009, Pages 261-271

  Becker, Claudia ^a   Meier, Christoph R ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cholesterol; HMG CoA reductase inhibitors; Neuroprotection; Observational studies; Parkinson disease; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; DEPRESSION; DRUG EXPOSURE; HUMAN; IDIOPATHIC DISEASE; LIVER TOXICITY; MUSCLE DISEASE; NONHUMAN; PARKINSON DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SLEEP DISORDER;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 67649307141     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902859956     Document Type: Review

References (109)

1. Galvan A, Wichmann T. Invited review: pathophysiology of parkinsonism. Clin Neurophysiol 2008;119:1459-1474
2. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596
3. Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998;44:S89-98 (Pubitemid 28423834)
4. Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005;11(Suppl 1):S9-15 (Pubitemid 40693572)
5. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S26-36; discussion S36-38 (Pubitemid 36368560)
6. Hardy J, Cai H, Cookson MR, et al. Genetics of Parkinson's disease and parkinsonsim. Ann Neurol 2006;60:389-398 • Comprehensive review on the genetics of PD.
7. Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S16-23; discussion S23-5 (Pubitemid 36368559)
8. Biskup S, Gerlach M, Kupsch A, et al. Genes associated with Parkinson syndrome. J Neurol 2008;255(Suppl 5):8-17 • Another recent review on the genetics of PD.
9. Mena MA, de Yebenes JG. Drug-induced parkinsonism. Exp Opin Drug Saf 2006;5:759-771 (Pubitemid 44669491)
10. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-535 (Pubitemid 44262284)
11. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: The Rotterdam Study. Neurology 1995;45:2143-2146 (Pubitemid 27100237)
12. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-386
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421 (Pubitemid 36005324)
14. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-239 (Pubitemid 38924592)
15. National Institute for Health and Clinical Excellence. CG67 Lipid modification: NICE guideline (issued 22 Sept 2008). Available from: http://www.nice.org.uk/nicemedia/pdf/CG67NICEGuideline.pdf. [Accessed at 31 Oct 2008]
16. Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 2002;23:207-215
17. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)
18. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. NEJM 2007;357:1477-1486 (Pubitemid 47572633)
19. Goldstein LB, Amarenco P, Lamonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008;39:2444-2448
20. Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009;112:4-12
21. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44
22. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118 •• Comprehensive review on pleiotopic statin effects. (Pubitemid 40261799)
23. Jick SS, Choi H, Li L, et al. Hyperlipidemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2008 In press
24. Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007;34:964-968 (Pubitemid 46774839)
25. Wekerle H. Tackling multiple sclerosis. Nature 2002;420:39-40
26. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multpile sclerosis. Lancet 2004;363:1607-1608 (Pubitemid 38625664)
27. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 2007;3:e1928
28. Haag MD, Hofmann A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2008 In press
29. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878-885 (Pubitemid 47329587)
30. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000;356:1627-1631 (Pubitemid 30835686)
31. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430 • Important contribution to the description of the mevalonate pathway. (Pubitemid 20065229)
32. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of Rho GTPase gene transcription. Circulation 2000;102:3104-3110
33. Sundaresan M, Yu ZX, Ferrans VJ, et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J 1996;318:379-382 (Pubitemid 26305933)
34. Zipp F, Waiczies S, Aktas O, et al. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 2007;28:342-349 (Pubitemid 47016681)
35. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2004;19:117-125 • Informative review on the properties of statins.
36. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005;96:11-23 (Pubitemid 41207729)
37. Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006;98(Suppl):34P-41P (Pubitemid 44779499)
38. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37 (Pubitemid 28094090)
39. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S49-58; discussion S58-60 (Pubitemid 36368562)
40. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004;10(Suppl 1):S3-7 (Pubitemid 38510423)
41. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007;150:963-976 (Pubitemid 46628616)
42. Greenamyre JT, Hastings TG. Biomedicine. Parkinson's - divergent causes, convergent mechanisms. Science 2004;304:1120-1122
43. Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 2007;414:94-97 (Pubitemid 46241643)
44. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006:61:262-274 (Pubitemid 43382625)
45. Yoshino G, Hirano T, Kazumi T, et al. Fluvastatin increases LDL-particle size and reduces oxidative stress in patients with hyperlipidemia. J Atheroscler Thromb 2003;10:343-347
46. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004;15:251-258 (Pubitemid 39061608)
47. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006;91:4489-4496 (Pubitemid 44833428)
48. Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005;1037:1-6
49. 2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res 2005;1045:229-233
50. Wang Q, Tang XN, Wang L, et al. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett 2006;408:189-193 (Pubitemid 44528870)
51. Obata T, Yamanaka Y. Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum. Brain Res 2000;860:166-169 (Pubitemid 30155851)
52. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995;1271:195-204
53. Hargreaves IP, Duncan AJ, Heales SJ, Land JM. The effect of HMG-CoA reductase inhibitors on Coenzyme Q10. Drug Saf 2005;28:659-676
54. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550
55. Müller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003;341:201-204 (Pubitemid 36403763)
56. Lieberman A, Lyons K, Levine J, Myerburg R. Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease. Parkinsonism Relat Disord 2005;11:81-84 (Pubitemid 40279146)
57. Somayajulu M, McCarthy S, Hung M, et al. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by coenzyme Q10. Neurobiol Dis 2005;18:618-627 (Pubitemid 40332719)
58. Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007;64:938-944
59. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-8934 (Pubitemid 120007623)
60. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-229 (Pubitemid 23129500)
61. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313-317 (Pubitemid 24167378)
62. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18(Suppl):S137-44 (Pubitemid 27372929)
63. Kaikkonen J, Nyyssönen K, Tuomainen TP, et al. Determinants of plasma coenzyme Q10 in humans. FEBS Lett 1999;443:163-166 (Pubitemid 29078624)
64. Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004;61:889-892 (Pubitemid 38747328)
65. Müller T, Kuhn W, Pohlau D, Przuntek H. Parkinsonism unmasked by lovastatin. Ann Neurol 1995;37:685-686
66. Müller T. Statin-induced Parkinson-syndrome. Letter to the editor regarding the article of J. Finsterer in "Der Nervenarzt" (2003) 74:115-122 Statininduziertes Parkinson-Syndrom. Leserbrief zum Beitrag von J. Finsterer in "Der Nervenarzt" (2003) 74:115-122. Nervenarzt 2003;74:726-727
67. Duits N, Bos FM. Depressive symptoms and cholesterol-lowering drugs. Lancet 1993;341:114 (Pubitemid 23028141)
68. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf 2007;30:195-201 (Pubitemid 46425633)
69. Sinzinger H, Mayr F, Schmid P, et al. Sleep disturbance and appetite loss after lovastatin. Lancet 1994;343:973 (Pubitemid 24117240)
70. Gregoor PJ. Atorvastatin may cause nightmares. BMJ 2006;332:950 (Pubitemid 44365553)
71. Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007;195:7-16 • Comprehensive overview of adverse effects of statins in clinical trials. (Pubitemid 47561937)
72. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389 (Pubitemid 24365311)
73. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
74. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with avarage cholesterol levels. N Engl J Med 1996;335:1001-1009 (Pubitemid 26338729)
75. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
76. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-1622 (Pubitemid 28248586)
77. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22 (Pubitemid 34756487)
78. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696 (Pubitemid 39140624)
79. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002;288:2998-3007
80. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630 (Pubitemid 35379733)
81. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006;164:998-1002 (Pubitemid 44729842)
82. Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord 2007;22:377-381 (Pubitemid 46569693)
83. de Lau LM, Stricker BH, Breteler MM. Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov Disord 2007;22:1985-1987 (Pubitemid 350134222)
84. Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf 2008;31:399-407 (Pubitemid 351563732)
85. Samii A, Carleton BC, Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci 2008;15:1272-1273
86. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology 2008;70:1418-1422
87. Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20 (Pubitemid 47337253)
88. Simon KC, Chen H, Schwarzschild MA, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and the risk of Parkinson disease. Neurology 2007;69:1688-1695 (Pubitemid 350287125)
89. Frigerio R, Elbaz A, Sanft KR, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 2005;65:1575-1583 (Pubitemid 41689471)
90. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007;64:990-997 (Pubitemid 47047999)
91. Elbaz A, Moisan F. Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 2008;21:454-460
92. Litvan I, Bhatia KP, Burn DJ, et al. Movement disorders society scientific issues committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-486
93. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301
94. Gerlach M, Hendrich A, Hueber R, et al. Early detection of Parkinson's disease: unmet needs. Neurodegener Dis 2008;5:137-139 (Pubitemid 351347831)
95. Michell AW, Lewis SJG, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain 2004;127:1693-1705 (Pubitemid 39061546)
96. Huang X, Abbott RD, Petrovitch H, et al. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 2008;23:1013-1018
97. Hu G, Antikainen R, Jousilahti P, et al. Total cholesterol and the risk of Parkinson disease. Neurology 2008;70:1972-1979
98. Stepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep 2005;57:561-569
99. Reiss AB, Wirkowski E. Role of HMG-CoA reductase inhibitors in neurological disorders. Drugs 2007;67:2111-2120
100. Schapira A, Olanow C. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004;291:358-364 (Pubitemid 38101609)
101. Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001;187:81-89 (Pubitemid 32611661)
102. Orr JD. Statins in the spectrum of neurologic disease. Curr Atheroscler Rep 2008;10:11-18
103. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211 •• A seminal paper on the stages of the development of PD. (Pubitemid 36007810)
104. Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-174 (Pubitemid 34810596)
105. Levesque LE, Delaney JA, Etminan M, Suissa S. Pharmacologic interventions for the prevention of Alzheimers's disease: an example of reverse protopathic bias [abstract no. 65]. 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 2006 Aug 24-27; Lisbon. Pharmacoepidemiol Drug Saf 2006;15:S31
106. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003;106:409-415 (Pubitemid 36870405)
107. Tamim H, Monfared AA, Lelorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007;16:250-258 (Pubitemid 46431688)
108. Marras C, Lang A. Invited article: Changing concepts in Parkinson disease. Neurology 2008;70:1996-2003
109. Weiner WJ. There is no Parkinson disease. Arch Neurol 2008;65:705-708